Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Eisai to Present Latest Data on Lemborexant at the 36th Annual Sleep 2022 Meeting
Details : DAYVIGO (Lemborexant), an orexin receptor antagonist, is Eisai’s in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2).
Brand Name : Dayvigo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 02, 2022
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Eisai To Present Latest Data Of Lemborexant At 35th Annual Sleep Meeting (SLEEP2021)
Details : DAYVIGO (lemborexant) is a small-molecule compound, discovered and developed by Eisai in-house scientists, that inhibits orexin signaling by binding competitively to both orexin receptor subtypes (orexin receptor 1 and 2).
Brand Name : Dayvigo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 09, 2021
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo® (Lemborexant) in Hong Kong
Details : DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm.
Brand Name : Dayvigo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 03, 2021
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The main presentations from Eisai at this conference include presentations relating to the SUNRISE 2 Phase III clinical trial conducted globally, including sites in Japan.
Brand Name : Dayvigo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 25, 2020
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Eisai to Launch In-House Developed New Anti-insomnia Drug in Japan
Details : DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R).
Brand Name : Dayvigo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 06, 2020
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In clinical studies, DAYVIGO helped some people with insomnia fall asleep faster and stay asleep longer compared to placebo. The effects of DAYVIGO at first use were generally consistent with later timepoints.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2020
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?